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ABSTRACT
Objectives: Human papillomavirus (HPV) ranks the first cause of cervical cancer. Cervical cancer has high prevalence rates 
in women around the world. The HPV-E7 oncoprotein is expressed in cervical cancer and is a target of developing immu-
notherapies against HPV-associated tumors. However, the antigenicity of this protein is low. Due to this reason, potent 
adjuvants are required to enhance its therapeutic efficacy. This preliminary study aims to evaluate whether lymphotoxin 
(LT) could act as an effective immune adjuvant for HPV infection in mice models. 
Material and methods: Intranasal immunization was used to explore the effect of HPV-E7 and/or LT immune response. 
After the third intranasal immunization, the titer for the HPV-E7 antibody was detected in serum and vaginal washing fluid. 
Also, we assessed the expression of chemokine ligand 13 (CXCL13) and Peripheral Node Addressin (PNAd) in the lymph 
nodes after intranasal immunization with immunohistochemical analysis.
Results: compared to HPV-E7 immunization, intranasal immunization with HPV-E7 plus LT significantly increased HPV-E7-spe-
cific serum IgG and vaginal IgA titers. Furthermore, the combined use of HPV-E7 and LT strongly induced E7-specific CTL 
responses. 
Conclusions: LT can be effective for intranasal immunized HPV-E7 to improve E7-specific immune responses to HPV infection.  
It is new approach to eradicate chronic HPV infection capable of inducing an effective anti-infection method.
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INTRODUCTION
Cervical cancer has high prevalence rates in women 
around the world [1, 2]. According to the World Health Or-
ganization (WHO) Human Papillomavirus and Related Can-
cers, World Summary Report 2010, every year, worldwide, 
HPV caused 500,000 new cases of cervical cancer [2]. Most 
HPV infections are harmless and clear up spontaneously; 
however, persistent HPV infections (especially type 16) have 
been reported could cause many human cancers such as 
cervical cancer and oropharyngeal cancer [3, 4]. 
HPV generally encodes six non-structural proteins (E1, 
E2, E6, E7 E5, E4) and two structural proteins (L1 and L2). 
These HPV encoded antigens are expressed differentially 
across the maturing cervical epithelium [1]. It has been 
reported that natural immune responses to HPV encoded 
antigens are typically weak and the immune responses 
vary among individuals, but the E7 protein is an exception 
to this [5]. The E7 protein is one of the proteins that could 
elicit a humoral immune response in most cases of invasive 
cervical cancer [5]. Due to its interactions with regulatory 
cellular proteins, e.g., p53 and pRb, HPV E7 protein could 
disrupt the normal cell cycle and the process of DNA repair, 
leading to neoplastic transformation and the immortaliza-
tion of epithelial cervical cells. Therefore, E7 is regarded as 
a powerful transforming oncoprotein target protein for HPV 
therapeutic strategies. It can directly against HPV infection 
to prevent and treat the cervical neoplasia [6]. 
There have been many different attempts to induce 
E7 specific immune responses in previous studies [7]. For 
example, Yang et al. [8] conducted a study and found that 
E7 peptide could induce antigen-specific T cells in animal 
subjects. However, to date, researchers have not been able 
to clinically demonstrate an effective therapeutic approach 
using this method. Several likely reasons exist for this, in-
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cluding the ability of HPV to evade immune recognition 
[9]. Therefore, there is an urgent need for novel therapies in 
order to eradicate HPV infection in the genital tract mucous 
membrane. 
Lymphotoxin (LT) is one of the members in tumor ne-
crosis factor (TNF) superfamily that has been shown to be 
an important component of effector immune responses. 
LT receptor pathway is essential to protect innate and adap-
tive immune and LT is essential for host defenses against spe-
cific pathogens, for example, it’s involved in the production 
of IgA and many other cytokines [10]. Lymphotoxin (LT) plays 
multiple roles in the immune system and autoimmunity. It’s 
reported that mucosal immunity is more effective against 
clear pathogens of mucous membrane infection than tra-
ditional immunization like oral administration and injection 
immunization [7]. Mucosal immunization can be achieved 
via oral, intranasal, pulmonary, rectal, or vaginal routes, and 
intranasal immunization with purified HPV16 VLPs induces 
systemic and mucosal antibody responses [7].Compared to 
vaginal and rectal mucosal immunity, intranasal immuniza-
tion is an ideal method to induce genital mucosal immune 
response because it is cost-effective and convenient [11, 12]. 
In consideration of the above, we conducted this pre-
liminary study to explore whether co-administration of 
E7 peptides and LT with the addition of cholera toxin (CT) 
elicits immune responses as well as protects against the 
tumor. Our results showed that intranasal co-administration 
of E7 peptides and LT induced stronger antigen-specific im-
mune responses in mice when compared to the response 
from E7 alone. Further, LT stimulation significantly enhanced 
E7-specific T-cell responses and CTL responses. We also 
demonstrated that co-administration of E7 peptides with 
LT could induce lymphocyte homing in the mouse models. 
MATERIAL AND METHODS
Animals
All C57BL/6 mice (female, 6–8 weeks old) were pur-
chased from Animal Center of Nanjing Medical University 
(Nanjing, China). Animals in this study were kept in the 
pathogen-free conditions. All animal care and experimental 
procedures were performed in accordance with recommen-
dations for the proper use and care of laboratory animals. 
The study was approved by the Ethics Committee of 
our hospital.
Recombinant E7 peptide and LT
Recombinant peptide of HPV-16 E7 protein (amino acids: 
31–50 SSEEEDEIDGPAGQ AEPDRA) was synthesized by the 
GL Biochem (Shanghai, China). The peptide purity was above 
98% as determined by reverse-phase high-performance 
liquid chromatography. E7 peptide was dissolved in dou-
ble-distilled H2O. All peptides that were not immediately 
used were stored at –20° C. LT with a purity of ﹥98%. was 
purchased from PeproTech (NJ, USA). 
Immunization of mice
Twenty-four mice were randomly assigned to four groups 
(n = 6 each): PBS control group, LT group, HPV-E7 group and 
HPV-E7 plus LT group. The mice in the four groups were 
lightly anesthetized with 10% ketamine and 5% xylazine in 
sterile water for the duration of the inoculation. The mice in 
HPV-E7 + LT group were immunized intranasally with 10 μg 
of HPV-E7 and 2 μg of cholera toxin (Sigma- Aldrich, MO, 
USA) and injected through the vena caudalis with 0.05 μg of 
Lymphotoxin in a total volume of 20 μL per mouse. The mice 
in HPV-E7 group were immunized intranasally with 10 μg of 
HPV-E7 and 2 μg of cholera toxin alone. The mice in the LT 
group received 0.05 μg of Lymphotoxin in a total volume 
of 20 μL per mouse and the PBS control group received 
PBS only. All mice in the four groups were immunized three 
times with the same dosage of the corresponding immune 
formulation at two-week intervals. The mice in control group 
were given PBS in the same volume on days 0, 14, and 28.
Collection of vaginal samples and serum
Samples of blood and vaginal were collected on day 0, 
14, 28, and 42 following intranasal immunization and/or 
LT injection. Blood samples were obtained by retro-orbital 
sinus puncture and clotted at room temperature for 60 min-
utes. After microcentrifuged at 1,700 g for 10 minutes, the 
serum was separated and then stored immediately at −20° C 
until analysis. In order to obtain the vaginal samples, 100 μL 
PBS were injected into the vaginal cavity. The vaginal sam-
ples were then washed five times in the lab.
Antibody Detection
HPV-E7 antibody titers were detected using en-
zyme-linked immunosorbent assay at dilutions of 100, 
200, 400, 800, 1600, 3200 for detections of IgG, and at 
delusions of 10, 20, 40 for detections of IgA. For detec-
tion of HPV-E7-specific vaginal IgA and serum IgG, high 
protein-binding 96-well plates (Invitrogen, Burlington, ON, 
Canada) were incubated overnight at 4°C, with a capture 
layer of 100 μL HPV-E7 peptide (50 μg/mL in carbonate 
buffer, pH 9.6). After three washes with PBS-0.05% Tween-20, 
the plates were blocked with 3% bovine serum albumin in 
PBS at room temperature for 2 to 4 hours, then samples 
were applied in duplicate at various dilutions in 3% bovine 
serum albumin-PBS as indicated in individual experiments, 
and incubated at 4° C overnight. The plates were washed 
five times, incubated with peroxidase-conjugated goat an-
ti-mouse IgA (Santa Cruz, CA, USA), diluted 1:5000 in 1% bo-
vine serum albumin-PBS or anti-mouse IgG (Santa Cruz, CA, 
USA), then diluted 1:2500, at room temperature for 1 hour. 
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After seven washes, 100 μL of TMB (Sigma Aldrich, MO, 
USA) were added to each well. Colorimetric reactions were 
performed at room temperature in the dark then stopped 
by adding 1N H2SO4. ODs were measured at 450 nm using 
a 96-well spectrophotometer (Microplate Reader Model 
680, BIO-RAD, USA). End point titers were determined and 
expressed as geometric mean titers. The mean background 
optical density value of non-immune mice was measured 
twice and used as the cutoff for determining positive values.
DC preparation
Spleen DC was obtained aseptically from C57BL/6 mice 
and placed in the PBS buffer. After dissociation, suspen-
sion was collected through a 400-mesh steel net. First, red 
blood cells were removed by adding ACK solution (Biofluids, 
Camarillo, CA) and the remaining cells were resuspended 
with RPMI1640 medium containing 10% fetal bovine serum, 
then counted. Non-adherent cells were disposed of and the 
remaining cells were divided into two parts. Spleen cells 
were labeled with 2.5 μmol/L Carboxy Fluoroscein Succin-
imidyl Ester (5- or 6-(N- uccinimidyloxycarbonyl)-3’,6’-0,0’- 
diacetyl-fluorescein, CFSE; Invitrogen, USA) (CFSE high) or 
0.25 μmol/L CFSE (CFSE low). CFSE high cells were then 
pulsed for 90 min at 37°C with either 2 μg/mL HPV-E7 or 
a survivin peptide as a control in a 5% CO2 incubator. After 
extensive washing, CFSE-high and low cells were mixed in 
a 1:1 ratio. 
Flow cytometric analysis
After being stimulated three times, the CFSE-high 
and CFSF-low cells (2 × 106, 100 μL) were mixed in a ra-
tio of 1:1 and injected intravenously or vaginally under 
light anesthesia. After 12 hours of administration, the 
spleen and uterus were processed into single cell suspen-
sions. Briefly, after perfusion with cold 1x PBS, the spleen 
was removed, minced into fragments, and digested with 
1 mg/mL collagenase (catalog no. 17018–029; Gibco) and 
0.1 mg/mL DNAase for 1 hour at 37°C with intermittent 
agitation. Spleen fragments were passed through a 400-
mesh steel net (Falcon; BD Biosciences). and approximately 
13–107 cells were incubated in 2.5 mg/mL Fc blocking 
solution, centrifuged (800 × g, 10 minutes, 8°C), and resus-
pended with FACS buffer.
Approximately 1 × 105 to 106 cells per sample were 
measured to assess the clearance rate of the target 
cells. The following formula was used: the specific killing rate 
(%) = [1 – (CFSE-low control/CFSE-high control)/(CFSE-low 
experimental/CFSE-high experimental)] × 100%. The formu-
la was used to measure the percent of cells that were killed. 
Data were acquired on a Becton Dickinson FACSCalibur flow 
cytometer and analyzed with FlowJo software (Tree Star Inc., 
Ashland, OR, USA).
Statistical analysis
All data are expressed as mean ± SD. Graphpad Prism 
(version 5; San Diego, USA) was used to construct figures and 
diagrams. One-way analysis of variance (ANOVA) or unpaired 
T-tests and Mann–Whitney tests were used where appropri-
ate. Differences were considered statistically significant if 
the p-value was less than 0.05. Error bars represent ± SD.
RESULTS
HPV-E7 plus LT enhances E7-specific systemic 
humoral immune response
To evaluate the adjuvant properties of LT in vivo, the 
geometric mean titers of the antigen-specific antibody 
were analyzed in this study. At two-week intervals, mice 
were administrated three times with the indicated amount 
of HPV-E7 plus LT, HPV-E7, LT, or PBS. In addition, CT was 
added in each group as a mucosal adjuvant. For 42 days, 
serum samples were collected after intranasal immuniza-
tion and titrated for HPV-E7-specific antibodies. Animals 
immunized with HPV-E7 showed detectable HPV-E7-specific 
antibodies. HPV-E7 plus LT elicited a significantly higher 
increase of HPV-E7-specific antibody levels compared to 
inoculation with HPV-E7 alone. However, the mice inocu-
lated with LT alone did not show any increase in humoral 
immune response (Fig. 1). These results indicated that LT 
could significantly enhance the HPV-E7 peptide-specific 
humoral immune response.
HPV-E7 plus LT enhances E7-specific vaginal 
humoral immune response
We also examined the adjuvant properties of LT in 
the HPV-E7-specific vaginal humoral immune response. 
The level of vaginal IgA was 1:40 in the HPV-E7 plus LT 
group and 1:20 in the HPV-E7 group (Fig. 2). At the dilution 
level of 1:20 and 1:40, the HPV-E7-specific antibody titers 
were higher in the HPV-E7 plus LT group than those in the 
HPV-E7 group. Our results demonstrated that a significant 
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Figure 1. Antibody response to HPV-E7 and/or LT in vivo. Mice were 
immunized with PBS, HPV-E7 and/or LT at two-week intervals. Serum 
was collected 42 days after immunization and diluted into different 
concentration. IgG responses against HPV-E7 were evaluated using 
ELISA; *p < 0.05 as compared to PBS control mice; #p < 0.05 as 
compared to HPV-E7 naive mice
304
Ginekologia Polska 2020, vol. 91, no. 6
www. journals.viamedica.pl/ginekologia_polska
HPV-E7-specific vaginal humoral immune response was 
induced by LT.
Immunization with HPV-E7 peptide plus LT 
stimulated enhanced systemic anti-HPV-E7 CTL 
responses 
We investigated whether HPV-E7 + LT immunization was 
able to induce anti-HPV-E7 CTL responses. The mice were 
immunized three times with HPV-E7 + LT, HPV-E7or PBS. 
The splenocytes of the immunized mice were stimulated 
with HPV-E7 and cytometric analysis was used to detect 
the activities of the target cells killed by HPV-E7-specific 
CTL. M1 represented CFSF-low cells and M2 represented 
CFSE-high cells (Fig. 3). M1 and M2 cells in the control group 
were substantially equal, there were no obvious cytotoxici-
ties of CTL or killing effects for target cells incubated with 
HPV-E7. There were fewer M2 cells than M1 cells in both the 
HPV-E7 and HPV-E7 + LT groups. This means that immuniza-
tion with HPV-E7 plus LT induced a significant increase of 
the HPV-E7-specific killing response in vivo. The killing rate 
of HPV-E7 + LT group was higher than that in HPV-E7 alone 
group (51.64% ± 3.07% vs 26.25% ± 5.04%, p < 0.05). And 
the killing rate of the PBS group was (6.16% ± 0.97%).
HPV-E7 peptide plus LT stimulated enhanced E7-
specific vaginal CTL responses 
To determine whether LT modulates a vaginal 
HPV-E7-specific response, vaginal samples were obtained 
and HPV-E7-specific IgA were examined. We found that the 
killing rates of the HPV-E7 + LT group increased significantly 
compared to HPV-E7 immunization alone (69.12% ± 9.01% 
vs 37.46 ± 4.03%, p < 0.05). Our results suggested that LT 
played an important role in the effect of CTL-mediated 
cytotoxicities (Fig. 4). 
HPV-E7 peptide plus LT induces lymph homing
In the present study, we assessed the capacity of 
protective T-cell subpopulations to home to the genital 
mucosa and associated lymphoid tissues in response to 
HPV-E7 and LT immunization. Tissue section morphometry 
of lymph nodes showed the mice that were immunized 
with HPV-E7 + LT had the most abundant CXCL13 and PNAd 
levels. The mice that were immunized with either PBS or LT 
alone had the lowest CXCL13 and PNAd levels. There were 
no differences in the PBS and LT immunization positive 
Figure 2. HPV E7-specific vaginal humoral immune response to 
HPV-E7 and/or LT in vivo. C57BL/6 mice were immunized with HPV-E7 
and/or LT at two-week intervals. Vaginal washes were collected after 
HPV-E7 and/or LT immunization for 42 days and diluted into different 
concentrations. HPV-E7-specific IgA antibodies were evaluated 
using ELISA; *p < 0.05 as compared to PBS control mice; #p < 0.05 as 
compared to HPV-E7 naive mice
Figure 3. Mice were immunized with PBS, HPV-E7 and/or LT at 
two-week intervals then injected with syngeneic CFSE-labeled 
splenocytes pulsed with E7 peptide to measure spontaneous 
cytotoxicity generated by CTL cells. The peptide-specific killing 
response in vivo was determined 7 d later. The killing rate of CTL was 
calculated using the following formula: the specific killing rate (%) = 
[1 – (CFSE-low control/CFSE-high control)/(CFSE-low experimental/ 
CFSE-high experimental)] × 100%; *p < 0.05 as compared to PBS 
control mice; #p < 0.05 as compared to HPV-E7 naive mice
Figure 4. Mice were immunized with PBS, HPV-E7, and/or LT then 
injected with syngeneic CFSE-labeled splenocytes pulsed with 
E7 peptide to measure vaginal specific cytotoxicity generated by 
CTL cells. HPV-E7-specific killing response in vaginal washes was 
determined 7 d later; *p < 0.05 as compared to PBS control mice;  
#p < 0.05 as compared to HPV-E7 naive mice
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areas regarding CXCL13 and PNAd. These results demon-
strate that HPV-E7 immunization contributes to lymphocyte 
homing to genital mucosa. Our findings that lymph nodes 
with HPV-E7+LT immunization express stronger lympho-
cyte “homing” chemokines CXCL13 and PNAd than those 
immunized with HPV-E7 alone, suggest that LT is critical 
to promoting lymphocyte homing induced by HPV-E7 im-
munization (Fig. 5).
DISCUSSION
Each year, worldwide, there are approximately 
529,000 newly diagnosed cases of cervical cancer, which 
have approximately a 50% mortality rate [13]. In the oc-
currence of cervical cancer, HPV plays an important role. 
Traditional methods to manage cervical cancer are focused 
on resolving the tumor. The methods to treat viral infection 
are usually neglected. Therefore, recurrence of cervical can-
cer often happens after successful treatment. To effectively 
eliminate HPV precancerous lesions and eliminate recur-
rence, therapeutic treatments for HPV infection are required. 
It has been reported that peptide-based immunotherapy is 
promising for resolving both cancer and HPV infection, but 
its full potential has yet to be investigated and its inherent 
limitations have not been overcome [14]. High-risk HPV-E7 is 
generally known as the most important oncogene of cervi-
cal cancer [6]. E7 is an HPV protein that is expressed during 
early phases of viral infections. Data indicates that E7 is 
capable of activating the specific CTL cells which act as ef-
fector cells to eliminate HPV infected cells by directly killing 
or releasing tumor inhibitive factors [15]. In this study we 
tested HPV-E7 as a target for an effective immune therapy 
and immune regulatory factors to eliminate HPV infection 
in the genital tract. It was difficult to induce intense im-
munoreactions and clear pathogens adhering to mucous 
surface using conventional subcutaneous immunization 
in genital mucosa. We chose to deliver HPV-E7 via the nasal 
route because this route had higher mucosal antibody titers 
than the other mucosal routes of immunization (oral, rectal, 
and vaginal) [15]. Also, we use CT to enhance HPV-E7-specific 
antibody response.
Intranasal immunization with HPV-E7 peptide 
stimulated enhanced E7-specific systemic and 
vaginal humoral and cellular immune responses
Most HPV infections begin at the mucosal surfaces; 
therefore, immunity against HPV infection might depend 
on the mucosal immune response [16]. This makes the mu-
cosal route the most appropriate way for immunization due 
to its ability to induce both mucosal and systemic immune 
responses [16]. Mucosal immunity is a special part of the 
immune system and is associated with most lymphoid tis-
sues (> 50%) characterized by common mucosal effects, 
including gut, nasal and urogenital associated lymphoid 
tissues [17]. Plasma cells and sensitized lymphocytes acti-
vated in inductive sites home to diffuse lymphoid tissues 
of various mucosae through interaction with lymphocyte 
homing receptors, endothelial cell adhesion molecules, 
and corresponding peripheral node addressins to induce 
immune response. Humoral and cell-mediated antigen 
immune responses can be induced by mucosal immuni-
zation. Mucosal immunization can be achieved via oral, 
intranasal, pulmonary, rectal, or vaginal routes [18–19]. 
It has been reported that intranasal immunization with pu-
rified HPV16 VLPs induces systemic and mucosal antibody 
responses [20]. Therefore, we used intranasal immunization 
to explore the effect of HPV-E7 and/or LT immune response. 
Figure 5. Mice were immunized with PBS, HPV-E7 and/or LT at two-week intervals. Representative images for the immunohistochemical staining of 
PNAd and CXCL13 in lymph nodes of different groups (400×)
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Also, CT was used as a mucosal adjuvant to enhance mucosal 
antibody response.
Two weeks after the third intranasal immunization in 
C57BL/6 mice, the titer for the HPV-E7 specific antibody was 
detected in the serum and vaginal washing fluid, following 
CT treatment. Our results showed that the titers for the 
HPV-E7 specific antibody in the serum and vaginal washing 
fluid were higher than in the control group following admin-
istration of CT, which suggested that appropriate humoral 
immunity responses were generated after HPV-E7 intranasal 
immunization.
LT is one of the members in the TNF superfamily and 
was originally identified as a lymphocyte product that was 
able to exert cytotoxic effects on tumor cells in vitro [10, 21]. 
Previous studies have found that LT-α and its complex play 
crucial roles in nasal-associated lymphoid tissue develop-
ment and function [22]. The cytokine LT is a promising can-
didate for use in cancer therapy. It is able to kill various 
specific cancer cells. Therefore, LT has received increased 
public attention and is considered a promising antitumor 
and antivirus biological agent.
In our study, we showed that HPV-E7, with the help of 
an LT adjuvant, following CT treatment, can elicit a signifi-
cant HPV-E7-specific response in the immune system and 
vaginal tract. We also found that HPV-E7 plus LT can elicit 
a strong E7-specific immune response in vivo, as evidenced 
by a significantly enhanced systemic and vaginal humoral 
immune response, cytotoxicity, and lymph homing, com-
pared with control groups. The data presented here dem-
onstrated that LT markedly promoted humoral and cellular 
responses of the immune system and genital tract mucosa 
after intranasal immunization with HPV-E7 following ad-
ministration of CT. LT can effectively strengthen the clear-
ance rate of HPV infected cells in the local genital tract by 
HPV-E7. It should be noted that the differences between 
HPV-E7 plus LT and HPV-E7 were only significant at high dilu-
tions, which needs further explorations in future studies and 
also needs improved to achieve a goal that at a much lower 
dilution, HPV-E7 plus LT can demonstrate a significant effect.
Hydrogen-bonded multilayered Tannic Acid (TA), a novel 
nanothin polymer material, showed similar effects to LT in 
anticancer immunotherapy [23]. TA was designed through 
hydrogen-bonded interactions of a natural polyphenol 
with poly (N-vinylpyrrolidone) (PVPON) deposited via 
layer-by-layer (LbL) assembly. The combination of TA and 
HPV-E7 with LT will be considered in future research [24]. 
LT stimulating HPV-E7 intranasal immunization 
by inducing lymph homing
The mucosal immune system is the first line to defense 
against pathogen invasion. Different parts of the mucosa 
can be connected by lymphocyte homing, generating 
a common immunological effect. The lymphocyte homing 
process is related to a variety of migrated molecule cascades 
that are involved in the lymphocyte homing process. These 
include lymphocyte homing receptors, addressins, and lym-
phatic chemotactic factors and their receptors. L-selectin, 
one of the lymphocyte homing receptors, is a member of the 
cellular adhesion molecular selectin family that participates 
in the process of lymphocyte homing and recycling [25]. 
PNAd is the ligand of L-selectin. It is first obtained from high 
endothelial venules of mice lymphocytes by monoclonal 
antibody MECA-79 and over-expressed in nasal-associated 
lymphoid tissue [26]. Lymphatic chemotactic factor CXCL13, 
also known as B-cell chemotactic factor, is a member of CXC 
chemotactic factor family. CXCL13 can induce the migration 
and homing of mature B lymphocytes after integrating with 
its receptors. 
This preliminary study found that adhesion molecules, 
lymphatic chemotactic factors, and addressins were low-ex-
pressed or non-expressed in LT knockout mice [22]. In this 
study, we used the lymphocyte homing related factors 
CXCL13 and PNAd to explore the possible target factors 
adjusted by LT in the lymphocyte homing pathway after 
intranasal immunization with HPV-E7. We found that the 
expression of CXCL13 and PNAd was elevated significantly 
in lymph nodes with HPV-E7 + LT immunization compared 
to those immunized with HPV-E7 alone. This demonstrates 
that LT regulates the immunological effects of intranasal 
immunization by stimulating activation and homing of 
lymphocytes.
  The immunogen used in this study is a recombinant 
peptide of HPV-16 E7 protein, which may not be able to 
protect against other subtypes of HPV virus. In addition, 
intranasal vaccination may not be so effective as intravaginal 
vaccination, but its advantage is that it’s convenient and has 
lower risks of infections.
In conclusion, specific humoral and cellular immune 
responses of the immune system and genital tract can be 
induced by intranasal administration of HPV-E7. LT can ef-
fectively promote the effects of intranasal immunization 
via regulating expression of lymphocyte homing related 
chemokines in the presence of CT. Further study is required 
to fully understand the detailed mechanism of regulating 
the homing factors of LT.
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